CA2718393A1 — Pyridylaminoacetic acid compound
Assigned to Ube Corp · Expires 2009-09-17 · 17y expired
What this patent protects
The present invention provides a pyridylaminoacetic acid compound represented by the following formula (1): (see formula 1) (wherein R1, R2, R3, Y and Z are as defmed in the description and claims), or a pharmacologically acceptable salt thereof. The pyridylaminoacetic acid compo…
USPTO Abstract
The present invention provides a pyridylaminoacetic acid compound represented by the following formula (1): (see formula 1) (wherein R1, R2, R3, Y and Z are as defmed in the description and claims), or a pharmacologically acceptable salt thereof. The pyridylaminoacetic acid compound has EP2 agonistic action and is therefore useful as a therapeutic and/or prophylactic agent for respiratory diseases such as asthma or chronic obstructive pulmonary disease.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.